Year 2018 turned out to be superb for the pharma and biotech sector as far as FDA approvals were concerned. The regulatory agency gave nod to 59 novel drugs, well above 46 drugs approved in 2017. Immuno-oncology was once again the key focus area in 2018, be it in terms of scientific conferences, clinical trial collaborations, acquisitions or FDA approvals.

The recently announced $74 billion mega-merger of two cancer giants, Bristol-Myers BMY and Celgene CELG, and

Read More At Article Source | Article Attribution